Cleveland

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Glioma, Tulane University School of Medicine, Cleveland Clinic, GVHD, Osteopathic medicine in the United States, University, Next Generation Science Standards, CD28, PSMA, Physician, Ohio University College of Arts and Sciences, American Society of Clinical Oncology, National Heart, Lung, and Blood Institute, Clinical and Translational Science Award, Drug, Head, Breast, Toxicity, Prostate, American Society of Hematology, Immunotherapy, Lung, Neck, Colon, NHLBI, Heritage College of Osteopathic Medicine, Wake Forest, Colorectal cancer, EGFR, Hematology, Wake Forest University School of Law, Renal cell carcinoma, American College of Physicians, American College, Cleveland, Therapy, Society, NIH, PD-L1, National Institutes of Health Clinical Center, Bone marrow, Pharmaceutical industry, Vaccine, Molecular medicine, Physics

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development.

Key Points: 
  • Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Dr. Zachariah (“Zach”) McIver as Vice President, Clinical Development.
  • “Zach has extensive clinical research experience including leading the clinical development to maximize the value of bispecific T-cell engager assets across multiple hematologic and solid tumor malignancies,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics.
  • “With TRACTr and TRACIr, Janux has built two very powerful platforms designed to overcome the toxicity and efficacy limitations of earlier generations of bispecific immunotherapies,” said Dr. McIver.
  • In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.

Dr. Kanwal Bawa, AKA Dr. Sex Fairy Is First To Offer PRX Intima Perfexion Intimate Skin Treatment In The US

Retrieved on: 
Tuesday, June 6, 2023
AKA, Medicine, ER, Cleveland Clinic, Emergency medicine, IV, MI, Life, Face, WIQO-FM, Elective surgery, Woman, Neck, Tunica intima, PRX, Patient, Cleveland, News, Skin, Birth control, Cosmetics

WOBURN, Mass., June 6, 2023 /PRNewswire/ -- PRX Intima Perfexion is a scientifically-backed skin beautification treatment that targets the external intimate areas of all genders.

Key Points: 
  • WOBURN, Mass., June 6, 2023 /PRNewswire/ -- PRX Intima Perfexion is a scientifically-backed skin beautification treatment that targets the external intimate areas of all genders.
  • Sex Fairy , a leading sexual wellness physician based in Boca Raton, Florida is the first in the US to offer PRX Intima Perfexion at her practice, Bawa Medical.
  • "We finally have a non-invasive way to rejuvenate the skin in intimate areas for both men and women," says Dr. Bawa.
  • "There is no downtime with Intima Perfexion treatments, and no peeling or skin irritation even on the day of the treatment.

New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing

Retrieved on: 
Saturday, June 3, 2023
Oncology, Health, Genetics, Clinical Trials, Research, Science, Biotechnology, CSD, CT, Cleveland Clinic, Radiation, Methylation, CSO, Cancer, Multimedia, CP/M, ASCO, Professor, American Society of Clinical Oncology, Patient, Physician, Memorial Sloan Kettering Cancer Center, Annual general meeting, PET/CT, Diagnosis, Cleveland, MPH, Society, Chair, Medical imaging, GRAIL, MD

The findings demonstrated that in the majority of cases (78%), the test’s CSO-directed initial diagnostic evaluation led to a diagnostic resolution.

Key Points: 
  • The findings demonstrated that in the majority of cases (78%), the test’s CSO-directed initial diagnostic evaluation led to a diagnostic resolution.
  • The findings were presented during a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Of those, the test’s CSO-directed predictions led to diagnostic resolution in 78% of cases (25/32).
  • Although whole-body imaging was useful for hematologic and indeterminate CSOs, it did not contribute to diagnostic resolution in 51% of the participants (20/39).

STV Taps Four Infrastructure Industry Experts to Lead its Newly Created Advisory Board

Retrieved on: 
Wednesday, May 24, 2023
Tufts University, Michigan Department of Transportation, Baltimore/Washington International Airport, Partnership, University, Port of Baltimore, STV, MBTA, Port, P.E, Risk management, Cleveland, Russian Industrial Leaders Index, Advisory board, Carnegie Mellon University, Australia, Central Maryland Transportation Alliance, MDOT, Engineering Society of Detroit, Vehicle registration plates of Nepal, Climate change, Investment, Engineering, Executive Committee, Water, Akridge, Georgia, Knowledge, Massachusetts Bay Transportation Authority, AEC, Beverley, Amtrak, The Fletcher School at Tufts University, Union Station, Management, Transport

NEW YORK, May 24, 2023 /PRNewswire/ -- STV, a professional services firm that plans, designs and manages infrastructure projects across North America, today announced the formation of a new Advisory Board featuring four industry experts: Joseph Aiello, former Massachusetts Bay Transportation Authority chairman, Karen Block, national water infrastructure leader, Kirk T. Steudle, former Michigan Department of Transportation director and Beverley Swaim-Staley, former Maryland Transportation secretary.

Key Points: 
  • The Advisory Board will provide STV with independent, strategic advice about the architectural, engineering and construction (AEC) industry, STV's markets and services, as well as help mentor and coach its next generation of leaders.
  • Earlier this year, STV launched its 2023-2025 Strategic Plan , and the new Advisory Board will support the firm in achieving its strategic ambitions.
  • He joined STV as a senior advisor in 2022 , and will expand his collaborations with STV teams in this new advisory role.
  • Karen Block: Karen has 30 years' experience directing market strategy, business development and sales activities in the infrastructure industry.

Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress

Retrieved on: 
Saturday, May 20, 2023
Health, General Health, Clinical Trials, Research, Science, Cardiology, Biotechnology, Heart failure, Protalix BioTherapeutics, Cleveland Clinic, Therapy, ERBB4, LVEF, EF, Death, Patient, Heart, European Society of Cardiology, Cleveland, Pharmaceutical industry

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction (HFrEF).

Key Points: 
  • Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced positive updated results from the ongoing Phase 1b study of JK07 in heart failure with reduced ejection fraction (HFrEF).
  • The data were presented in a late breaking oral session during the annual congress of the European Society of Cardiology’s Heart Failure Association.
  • JK07 is the first investigational antibody fusion protein and first selective ErbB4 agonist to enter clinical development for heart failure.
  • Heart failure is a serious health condition that contributes to one in eight deaths in the U.S. and impacts nearly 6.5 million Americans1.

New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias

Retrieved on: 
Friday, May 19, 2023
Abstract, Cardiac electrophysiology, PURE, Cleveland Clinic, PVI, Atrial fibrillation, Stroke, 3D, OH, New product development, Cardiac muscle, Radiofrequency ablation, EGM, MBA, Ablation, Conductor, Hospital, Heart Rhythm, MD, Physician, Risk, Electrophysiology, Arrhythmia, Cleveland, FDA, Pig, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, Medical device

Across all three studies, researchers compared the efficacy of using unipolar signals to guide procedures to the current standard of using an Ablation Index™.

Key Points: 
  • Across all three studies, researchers compared the efficacy of using unipolar signals to guide procedures to the current standard of using an Ablation Index™.
  • "These studies suggest that the preservation of raw cardiac signal enables the use of unipolar signals to help guide ablations, while improving lesion precision and reducing procedure time."
  • The PURE EP™ engineering enables physicians to access the value of unipolar radiofrequency guidance, established by previous studies.
  • A single gap was left in the linear application of the fifth model due to a misinterpretation of the unipolar EGM during pacing.

Ohio’s Growing Shale Energy Industry Attracted $2.8 Billion in Direct Investment in First Half of 2022, With Cumulative Investment Surpassing $100 Billion

Retrieved on: 
Tuesday, May 16, 2023
Plastic, Cleveland State University, CSU, OH, COVID-19, Ohio Department of Natural Resources, Head, Oil, Maxine, Maxine Goodman Levin College of Urban Affairs, Natural Resources, Investment, Natural gas, United States Department of Justice Environment and Natural Resources Division, Cleveland, ODNR, Renewable energy, Petroleum

Prepared for JobsOhio, the latest report covers shale investment from January through June 2022 and cumulates total investment from 2011 forward.

Key Points: 
  • Prepared for JobsOhio, the latest report covers shale investment from January through June 2022 and cumulates total investment from 2011 forward.
  • Of this, $70.8 billion has been in upstream, $21.5 billion in midstream, and $8.3 billion in downstream industries.
  • The study showed that cumulative shale investment steadily rose between 2016 and 2022, particularly with upstream investments.
  • Of that $53 billion in imports, nearly half originate in Asia, with China alone accounting for $25 billion.

EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Wednesday, May 3, 2023
Retinal detachment, Maintenance, ARVO, CALM, Cleveland Clinic, Therapy, DME, AMD, Clinical trial, Geographic atrophy, Research, Diabetic retinopathy, SOE, Congress, MD, Patient, Data, Investment, Annual general meeting, Webcast, Paratriathlon, POC, Cleveland, European Society of Gynaecological Oncology, Hand, Society, ASRS, C5, Pharmaceutical industry, Video game

WATERTOWN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended March 31, 2023 and highlighted recent corporate developments.

Key Points: 
  • ET
    WATERTOWN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended March 31, 2023 and highlighted recent corporate developments.
  • We look forward to announcing topline data from the DAVIO 2 trial in the fourth quarter of this year,” said Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals.
  • Review of Results for the First Quarter Ended March 31, 2023
    For the first quarter ended March 31, 2023, total net revenue was $7.7 million compared to $9.3 million for the quarter ended March 31, 2022.
  • ET to discuss the results for the first quarter ended March 31, 2023 and recent corporate developments.

EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Retrieved on: 
Friday, April 28, 2023
National Center for Complementary and Integrative Health, Sclerosis, Inauguration, Vincent, Cleveland Clinic, Short course immune induction therapy, University, Biogen, Biotechnology, National Center for Research Resources, National Multiple Sclerosis Society, American Academy, Multiple sclerosis, Innovation Unit, Bangladesh Technical Education Board, Cleveland, Advisory Council, Presidential Advisory Council on HIV/AIDS, Council, Neurology, Knowledge, Faculty, Case Western Reserve University School of Medicine, American Academy of Neurology, History of Cleveland Clinic, Holding company, Pharmaceutical industry, Management, Research

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Key Points: 
  • Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
  • Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
  • The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023.
  • “We are very grateful to have Rick join us,” stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic.

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.

Retrieved on: 
Thursday, April 27, 2023
National Center for Advancing Translational Sciences, Sclerosis, Inauguration, Vincent, Cleveland Clinic, Short course immune induction therapy, University, Biogen, National Center for Research Resources, National Multiple Sclerosis Society, American Academy, Multiple sclerosis, Innovation Unit, Bangladesh Technical Education Board, Cleveland, Advisory Council, Presidential Advisory Council on HIV/AIDS, Council, Neurology, Knowledge, Faculty, Case Western Reserve University School of Medicine, American Academy of Neurology, History of Cleveland Clinic, Pharmaceutical industry, Management, Research

NEW YORK, April 27, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Richard Rudick, M.D., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective April 26, 2023. The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023.

Key Points: 
  • The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023.
  • "We are very grateful to have Rick join us," stated Duane Nash, M.D., J.D., M.B.A., Chairman of the Board of Directors of Immunic.
  • He has published extensively and been an active participant and leader in developing the current treatment landscape for multiple sclerosis.
  • "On behalf of the entire Board of Directors, I would like to thank Vincent for his dedication to Immunic and his thoughtful guidance over the past seven years.